| (Values in U.S. Thousands) | Jun, 2015 | Jun, 2014 | Jun, 2013 | Jun, 2012 | Jun, 2011 |
| Sales | 0 | 0 | 17,860 | 0 | 29,640 |
| Sales Growth | unch | -100.00% | unch | -100.00% | +595.77% |
| Net Income | -43,920 | -20,380 | 20 | -12,230 | 12,890 |
| Net Income Growth | -115.51% | -102,000.00% | +100.16% | -194.88% | +170.48% |
Transition Therapeut (TTHI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol `TTHI` and the Toronto Stock Exchange under the symbol `TTH`.
Fiscal Year End Date: 06/30